STXS
Stereotaxis, Inc.2.3800
+0.0600+2.59%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
222.11MP/E (TTM)
-Basic EPS (TTM)
-0.28Dividend Yield
0%Recent Filings
10-K
FY2025 results
Stereotaxis posted FY2025 revenue of $32.4M, up 20% y/y, with systems at $10.2M (+18%) and disposables/service/accessories at $22.2M (+21%), fueled by the APT acquisition and service gains, though system backlog shrank to $9.1M from $14.4M. Gross margin held steady at 53%, but operating loss narrowed to $22.1M amid steady R&D and sales spend. Q4 momentum showed in regulatory wins like GenesisX FDA clearance and MAGiC catheter approvals, yet J&J catheter supply ends Dec 31 risks procedure volumes. Cash burn eased to $13.7M with $13.4M on hand post-equity raises; no debt. Supply chain snarls threaten quarterly rollout.
8-K
2025 revenue up 20%
8-K
Q3 revenue $7.5M, recurring up
Stereotaxis reported Q3 2025 revenue of $7.5 million, down from $9.2 million last year due to lower system sales of $1.9 million versus $4.4 million, yet recurring revenue climbed to $5.6 million from $4.8 million on Map-iT and new MAGiC launches. Gross margin held at 55%. Cash stands at $10.5 million, no debt. Q4 revenue tops $9 million; growth persists.
10-Q
Q3 FY2025 results
Stereotaxis posted Q3 revenue of $7.5M, down 19% y/y yet up on surging disposables, service, and accessories at $5.6M (+17% y/y) while systems fell to $1.9M; gross margin held steady at 55%. YTD revenue climbed 15% to $23.7M, with disposables mix driving the gain, but operating loss narrowed to $16.5M from $17.1M y/y as R&D and sales dipped. Cash burned $9.7M in operations; $10.5M remains on hand post-July equity raise. APT acquisition closed July 2024 for $3.0M stock plus up to $24.0M contingent earnouts (through 2029), adding $3.8M goodwill and $7.7M intangibles (7.7-year average life). Supply chain disruptions threaten timelines.
8-K
ATM stock sales pact
Stereotaxis inked a sales agreement with Roth Capital on August 29, 2025, enabling at-the-market offerings of up to $50 million in common stock. Proceeds will fuel working capital, R&D, and faster rollout of its innovation pipeline. No sales are guaranteed; it hinges on market vibes and company needs. This bolsters liquidity amid growth pushes.
IPO
Website
Employees
Sector
Industry
BAX
Baxter International Inc.
19.05-0.48
BDX
Becton, Dickinson and Company
196.39-3.70
BSX
Boston Scientific Corporation
92.95+0.76
ISRG
Intuitive Surgical, Inc.
554.58-4.94
MBOT
Microbot Medical Inc.
2.22+0.01
MMSI
Merit Medical Systems, Inc.
86.85+0.44
SSII
SS Innovations International In
5.50+0.41
STE
STERIS plc (Ireland)
253.03-1.04
SYK
Stryker Corporation
351.69-3.62
VTAK
Catheter Precision, Inc.
2.19-0.04